GLP-1s May Help Reduce Endometrial Cancer Risk in Patients With Obesity and Metabolic Disease

In this interview with Pharmacy Times, Jennifer MacDonald, PharmD, BCOP, discusses the growing evidence linking glucagon-like peptide-1 (GLP-1) receptor agonists to a reduced risk of endometrial cancer in patients with obesity and metabolic disease. MacDonald explains how rising rates of endometrial cancer, particularly aggressive forms disproportionately affecting Black and African American women, highlight the importance of preventive strategies targeting obesity and metabolic syndrome. She also discusses the evolving role of pharmacists in identifying high-risk patients and educating providers about integrating GLP-1 therapies alongside traditional progestin-based approaches for conditions such as endometriosis, PCOS, atypical hyperplasia, and fertility-preserving treatment strategies. MacDonald is an oncology clinical pharmacy specialist and director of the PGY2 oncology residency program at the Medical University of South Carolina in Charleston.